CARVER JENNIFER 4
4 · REVELATION BIOSCIENCES, INC. · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Revelation Biosciences (REVB) Director Jennifer Carver Sells 1,661 Shares
What Happened
Jennifer Carver, a director of Revelation Biosciences (REVB), had 1,661 shares disposed on Feb 3, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock. The weighted average price was $1.87 (sales occurred at $1.87–$1.88), resulting in proceeds of roughly $3,106. This was a mandatory tax-withholding sale, not a voluntary open-market sell for investment reasons.
Key Details
- Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (timely filing).
- Shares sold/Disposed: 1,661 at a weighted average price of $1.87 (range $1.87–$1.88).
- Reported proceeds: approximately $3,106.
- Shares owned after transaction: not specified in this Form 4.
- Footnotes: F2 indicates the shares were sold by the issuer solely to satisfy required tax obligations (mandatory, no investment discretion). F1 notes all share counts reflect a 1-for-4 reverse split effective Jan 28, 2026. F3 explains the reported price is a weighted average across multiple sale prices; breakdown available on request.
- Transaction code: F = tax withholding (cashless sale to cover taxes).
Context
Tax-withholding sales on vesting of restricted stock are routine administrative transactions and do not necessarily indicate the insider’s view on the company’s prospects. This was not an option exercise for cash gain or an open-market discretionary sale by the director.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2][F3]2026-02-03$1.87/sh−1,661$3,106→ 12,758 total
Footnotes (3)
- [F1]All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
- [F2]Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.